Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent patients achieved primary endpoint with a BMI decrease greater than 5 percent at 16... | November 2, 2022

Related Keywords

Boston ,Massachusetts ,United States ,San Diego ,California ,United Kingdom ,Adam Daley ,Christian Roth ,Hannah Deresiewicz ,David Meeker ,David Connolly ,Stern Investor Relations Inc ,Division Of Endocrinology ,Nasdaq ,University Of Washington ,European Union ,Seattle Children Research Institute ,Drug Administration ,European Commission ,Rhythm Pharmaceuticals ,Exchange Commission ,Us Food Drug Administration ,Rhythm Pharmaceuticals Inc ,Obesity Society Obesityweek ,Berry Company Public Relations ,Corporate Communications ,Department Of Pediatrics ,Medicines Healthcare Products Regulatory Agency ,Obesity Society ,Breakthrough Therapy ,Seattle Children ,Research Institute ,Long Term Extension ,Chief Executive Officer ,Breakthrough Therapy Designation ,Investor Relations ,Healthcare Products Regulatory Agency ,Rhythm Engine ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Quarterly Report ,Nc Stock Exchange ,News ,Information ,Press Release ,Hase , ,Linical ,Trial ,Design ,Eflects ,Feedback ,Btained ,During ,Ecent ,Discussions ,Ith ,Fda ,9 ,Ercent ,Patients ,Chieved ,Primary ,Ndpoint ,Mi ,Decrease ,Greater ,Han ,T Rytm Us76243j1051 ,